CTLA-4 inhibitors are associated with a higher risk of cardiovascular events than PD-1 inhibitors in Patients with Melanoma
Published: 20 February 2025| Version 1 | DOI: 10.17632/zrzgy3yzvc.1
Contributor:
Shao-Wei LoDescription
Supplemental material
Files
Categories
Biomedical Materials